Gaming and Training Combined to Help Adolescents Get More Physically Active

Sedentary Lifestyle Clinical Trial

Official title:

Increasing Physical Activity Among Adolescents With Motivational High-Intensity Training Through a Cutting-Edge Gaming Platform

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03663699
• Other study ID #: 2018/633
• Status: Terminated
• Phase: N/A
• Start date: February 11, 2019
• Est. completion date: April 7, 2021

Study information

• Verified date: April 2021
• Source: Norwegian University of Science and Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate if playing a newly developed videogame that requires physical activity (e.g. exergame), leads to increased physical activity and health benefits in children and adolescents who do not regularly participate in endurance training. Health benefits will be expressed in physical fitness (maximal oxygen consumption), blood markers of a healthy heart, body composition and objectively measured physical activity. Gaming frequency of the participants will be registered throughout the 24 week intervention period.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 29
• Est. completion date: April 7, 2021
• Est. primary completion date: April 7, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 18 Years

Eligibility

Inclusion Criteria:

• Not regularly participating in endurance training
• Sedentary (<60 mins daily moderate/vigorous intensity physical activity)
• Play video games > 10 hours/week (self-reported)
• Able to ride a bike for up to 60 minutes

Exclusion Criteria:

• Known cardiovascular disease
• Type I diabetes

Related Conditions & MeSH terms

• Sedentary Lifestyle

Intervention

Behavioral:
• Exergaming
free access to the exergaming platform PlayPulse for 24 weeks

Locations

Country	Name	City	State
Norway	Department of Circulation and Medical Imaging	Trondheim

Sponsors (1)

Lead Sponsor	Collaborator
Norwegian University of Science and Technology

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	VO2max	Maximal Aerobic Capacity	12 weeks
Primary	VO2max	Maximal Aerobic Capacity	24 weeks
Secondary	Change in daily average energy expenditure	Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 12 weeks and 24 weeks.	Baseline, 12 and 24 weeks
Secondary	Change in daily time in sedentary activity (<3.0 metabolic equivalents =METs)	Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 12 weeks and 24 weeks.	Baseline, 12 and 24 weeks
Secondary	Change in daily time in moderate intensity activity (3.0-6.0 metabolic equivalents = METs)	Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 12 weeks and 24 weeks.	Baseline, 12 and 24 weeks
Secondary	Change in daily time in vigorous intensity activity (6.0-9.0 metabolic equivalents = METs)	Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 12 weeks and 24 weeks.	Baseline, 12 and 24 weeks
Secondary	Change in daily time in very vigorous intensity activity (>9.0 metabolic equivalents = METs)	Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 12 weeks and 24 weeks.	Baseline, 12 and 24 weeks
Secondary	Change in daily average total physical activity duration	Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 12 weeks and 24 weeks.	Baseline, 12 and 24 weeks
Secondary	Change in daily average number of steps	Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 12 weeks and 24 weeks.	Baseline, 12 and 24 weeks
Secondary	Bioelectrical impedance	Body composition assessed using bioelectrical impedance analysis (InBody 720)	12 and 24 weeks
Secondary	systolic Blood Pressure		12 and 24 weeks
Secondary	Diastolic Blood Pressure		12 and 24 weeks
Secondary	Fasting circulating glucose, as blood marker of cardiometabolic health		24 weeks
Secondary	Lipid profile, as blood marker of cardiometabolic health		24 weeks
Secondary	Circulating insulin concentration, as blood marker of cardiometabolic health		24 weeks
Secondary	HbA1c from blood samples		24 weeks